Global CNS Therapeutics Industry

  • February 2013
  • -
  • Global Industry Analysts
  • -
  • 1058 pages

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia and ADHD). The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018.

The report profiles 127 companies including many key and niche players such as AbbVie Inc., Alkermes Plc, Amneal Pharmaceuticals, LLC, Aspen Pharmacare Holdings Limited, AstraZeneca Plc, BEACON Pharmaceutical Limited, BIAL Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Elan Corporation Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fabre-Kramer Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Sanofi S.A, Shire Plc, Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and UCB Group.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3
CNS Disorders I-3
Anti-Alzheimer's Drugs I-3
Anti-Parkinson's Drugs I-4
Anti-Epilepsy Drugs I-4
Pain Management Drugs I-4
Anti-Psychotics Drugs I-5
Bipolar disorder I-5
Schizophrenia I-5
Anti-Depressants Drugs I-5
Others I-6
Attention Deficit Hyperactivity Disorder I-6
Multiple Sclerosis I-6
Insomnia I-6
Restless Legs Syndrome I-7
Anxiety I-7


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
CNS Diseases, Treatment and Therapeutics: A Primer II-1
CNS Drugs: The Next Big Thing in the Healthcare Industry II-1
Major Growth Drivers in a Capsule II-2
Noteworthy Market Trends/Drivers and Issues II-2
Aging Population: A Key Demand Propellant II-2
Table 1: Percentage Share Breakdown of Global Population by
Age Group, Worldwide: 2025 (includes corresponding
Graph/Chart) II-3

Table 2: World Population of People Aged 65+ Years (In
Million) for Years 2012, 2020 and 2050 (includes corresponding
Graph/Chart) II-4
Developments in CNS Drug Delivery Technologies Bode Well for
the CNS Drugs Market II-4
Understanding of BBB Cell Biology and Its Positive Impact on
Epilepsy Drugs: A Case-in-Point II-4
Healthcare Cost Rationing and Government Caps Challenge Branded
CNS Drugs II-5
Slew of Imminent Patent Expiries to Exert Downward Pressure
on the CNS Drugs Market II-6
Patent Expiries of Leading CNS Drugs: 2008-2022 II-7
Branded Generic CNS Drugs: A Key Revenue Spinner in Emerging
Countries II-8
Focused RandD Efforts: Need of the Hour II-8
Need Factor in the Epilepsy Market: A Case-In-Point II-8
Pharma Companies: Seeking New Tools to Offset Pressure on
Drug Pipelines II-9
Huge Unmet Medical Needs Underpin Market Potential II-10
A Special Focus on the Unmet Needs in Epilepsy II-10
Awareness Campaigns Launched by Pharma Companies to Benefit
the Market II-11

2. MARKET OVERVIEW and TRENDS ACROSS CNS THERAPEUTIC AREAS II-12
Anti-Epilepsy II-12
Market Overview II-12
Table 3: Global Sales of Select Leading Anti-Epilepsy Drug
Brands In US$ Million for the Year 2011 (includes
corresponding Graph/Chart) II-13
A Peek into Select Epilepsy Drugs Currently Available in the
Marketplace II-13
A Peek Into Few of the Popular Anti-Epileptic Drugs and
Their Mechanism of Action II-15
Higher Incidences in Developing Countries II-15
Abounding Potential for NCEs II-15
A Peek into Select Epilepsy Drugs in Clinical Development As
of the Year 2012 II-16
A Peek into Select Anti-Epileptic Drugs Approved in the
Years 2011 and 2012 II-17
Pregnancy Safe Anti-Epileptic Drugs: Need of the Hour II-17
CNS Pain Management II-17
Market Overview II-17
Combination Therapies Gain Prominence II-18
Migraine Market Offers Growth Opportunities to Prophylaxis
Products II-18
Neuropathic Pain Management: A Potential Laden Market II-19
Strong Product Pipeline to Benefit the Neuropathic Pain
Management Market II-19
Anti-Alzheimer's II-20
Market Overview II-20
Anti-Parkinson's II-20
Market Overview II-20
Anti-Depressants II-21
Market Overview II-21
Attention Deficit Hyperactivity Disorder (ADHD) II-21
Market Overview II-21
Anti-Psychotics II-22
Market Overview II-22
Prevalence of Schizophrenia and Bipolar Disorders:
Statistical Snippets II-22
Second Generation Antipsychotics Beset With Safety Issues II-23
Companies Focus on Next Generation Products To Deflect the
Heat of Competition II-23
Table 4: World Antipsychotics Market (2011): Sales of
Leading Drug Brands - Seroquel IR, Seroquel XR, Abilify,
Zyprexa and Zyprexa Relprevv, Risperdal and Risperdal Consta,
Geodon, and Invega and Invega Sustenna (In US$ Million)
(includes corresponding Graph/Chart) II-24
A Peek into Anti-Psychotic Drugs in Late-Stage Clinical
Development As of 2012 II-25

3. CHANGING HEALTHCARE INDUSTRY IN EUROPE and THE UNITED STATES II-26
Healthcare Economics, the Eurozone Crisis and Changing Role of
the Government in Europe's Healthcare System II-26
Impact of Europe’s Rationing Healthcare System On CNS Drugs II-27
Impact On Pharma Companies in Europe II-28
Outlook for CNS Therapeutics in the United States in Light of
the Fiscal Cliff II-30

4. PRODUCT OVERVIEW II-32
Definition II-32
Central Nervous System II-32
Mortality Threat of CNS Disorders II-32
Science of NMDA Receptors and its Disease Significance II-32
Major CNS Disorders: II-33
Alzheimer’s Disease II-33
Alzheimer’s Affect on Brain II-33
Causes for Alzheimer’s II-34
Who Are at Risk? II-34
Prevalence of Alzheimer’s Disease II-35
Diagnosis of Alzheimer’s II-35
Treatment for Alzheimer’s II-35
Parkinson’s Disease II-36
Prevalence of Parkinson’s II-36
Symptom of Parkinson’s II-36
Causes of Parkinson’s II-37
Parkinson’s Diagnosis II-37
Therapies for Parkinson’s II-38
Surgery: The Last Option II-38
Epilepsy II-38
Causes of Epilepsy II-38
Symptoms of Epilepsy II-39
Types of Epilepsy and Epileptic Seizures II-39
Preventive Measures II-40
Treatment Options for Epilepsy Patients II-40
Treatment Options Available for Epilepsy Patients II-41
Epilepsy Drug Treatment Paradigm II-41
Pain Management II-41
Debilitating Effects of Pain II-42
Types of Pain II-42
Acute Pain II-42
Chronic Pain II-42
Migraine II-43
Neuropathic Pain II-43
Nociceptive Pain II-43
Pain Management Therapies II-43
Bipolar Disorder II-44
Symptoms of Bipolar Disorder II-44
Mood Episode - A Major Symptom II-44
Manic Episode Vs Depressive Episode II-45
Causes of Bipolar Disorder II-45
Types of Bipolar Disorder II-46
Co-morbidities of Bipolar Disorder II-46
Schizophrenia II-46
Prevalence by Gender II-47
Symptoms of Schizophrenia II-47
Causes of Schizophrenia II-48
Therapies for Bipolar Disorder and Schizophrenia II-48
Mood Stabilizing Agents II-49
Antidepressants II-49
Antipsychotic Drugs II-49
Indications of Antipsychotics II-50
An Effective Adjunctive Therapy II-50
Off-label Uses II-50
Efficacy - Marred by Lack of Evidence Base II-50
Types of Antipsychotics II-51
Difference between Typical and Atypical II-51
Atypical Antipsychotics Up Against Typicals II-51
Side Effects of Antipsychotics II-52
Symptoms of Antipsychotics Withdrawal II-53
Controversies Surrounding Antipsychotics II-54
Prohibited Practices II-54
Antipsychotics in Pregnant Women II-54
Depression II-55
Prevalence of Depression II-55
Causes of Depression II-55
Types of Depressive Disorders II-56
Available Treatment II-56
Tricyclic Antidepressants II-56
Monoamine Oxidase Inhibitors II-56
Lithium Salts II-56
Working of Antidepressants II-57
Ranking of Antidepressants in Terms of Efficacy II-57
Types of Antidepressants II-57
NMDA Receptor Antagonists II-57
NMDA Receptor (NMDAR) II-57
NMDA Receptor Agonists II-58
Acetylcholinesterase Inhibitors II-58
Selective Serotonin Reuptake Inhibitors (SSRIs) II-58
Workings of SSRIs II-59
Safety Levels of SSRI Drugs II-59
Adverse Effects of SSRI II-59
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) II-59
Others Common CNS Disorders II-60
Attention Deficit Hyperactivity Disorder II-60
Consequences of ADHD II-60
What Leads to ADHD? II-60
Treating ADHD II-61
Multiple Sclerosis (MS) II-61
Types of Multiple Sclerosis II-61
Prevalence of MS II-62
Causes of MS II-62
Myths Surrounding Multiple Sclerosis II-62
Symptoms of MS II-62
Diagnosis of MS II-62
Therapies for MS II-63
Insomnia II-63
Prevalence of Insomnia II-63
Therapies for Insomnia II-63
Restless Legs Syndrome II-63
Anxiety II-64

5. REVIEW OF SELECT CNS DRUGS II-65
Anti-Alzheimer’s Drugs II-65
Aricept II-65
Exelon II-65
Reminyl II-65
Ebixa II-65
Namenda II-65
Anti-Parkinson’s Drugs II-66
Levodopa II-66
Dopamine Agonists II-66
Mirapex II-66
Requip II-66
Anti-Epilepsy Drugs II-66
Vimpat® II-67
Keppra® II-67
Lamictal II-68
Tegretol® II-68
Sabril® II-68
Perampanel II-68
Zonegran® II-68
Topamax® II-69
Trileptal® II-69
Neurontin® II-69
Lyrica® II-69
Depakine® II-69
Pain Management II-70
Flupirtine II-70
Lyrica® II-70
Oxycodone II-70
Nucynta ER II-70
Cymbalta® II-70
Metabotropic Glutamate Receptors (mGluRs) II-70
Anti-Psychotic Drugs II-71
Zyprexa II-71
Seroquel II-71
Abilify II-72
Clozaril II-72
Risperdal II-72
Risperdal® Consta® II-72
Geodon II-73
Invega Sustenna II-73
Saphris II-73
Latuda II-73
Antidepressants Drugs II-74
Zoloft (Sertraline) II-74
Prozac (Fluoxetine) II-74
Effexor (Venlafaxine) II-74
Paxil II-74
Wellbutrin (Bupropion) II-74
Attention Deficit Hyperactivity Disorder (ADHD) II-75
Concerta II-75
Strattera II-75
Adderall II-75
Insomnia II-75
Zolpidem II-76
Eszopiclone II-76

6. RESEARCH and DEVELOPMENT II-77
Research Finds Higher Diabetes Risk among Antipsychotic-
Treated Patients II-77
Zonisamide is Effective in Epilepsy Prevention in Children II-77
Latuda Effective in Bipolar I Depression Treatment II-77
Cariprazine Effective in Bipolar I Disorder Treatment II-78
Alkermes Initiates Phase III Clinical Trials of Invega
Sustenna II-78
Antipsychotics Increase Mortality Risk in Dementia Patients II-78
Potential Antipsychotic Drug Fails in Clinical Study II-79
Pfizer Discontinues Clinical Trial of Lyrica Capsules CV II-79
Cariprazine Shows Efficacy in Acute Schizophrenia Treatment II-79
Prevention of Neuropathic Pain through Saxitoxin Dexamethasone
Liposomes II-79
Perampanel Effective in Reducing Epileptic Seizures II-80
Targacept Initiates Trials of its Novel Schizophrenia Drug II-80
Vertex Develops VX-765 for Epilepsy II-80
ALKS 9070 Effective in Treatment of Schizophrenia II-80
Lyrica Effective in Central Neuropathic Pain Following Spinal
Cord Injury II-81
UCB’s Vimpat Reduces Partial-Onset Seizure II-81
Eisai Announces Encouraging Results for Perampanel II-81

7. PRODUCT INTRODUCTIONS/INNOVATIONS II-82
Eisai Launches Fycompa II-82
Dr Reddy’s Unveils Generic Zyprexa in the US II-82
Eisai Europe Launches Zebinix® Eslicarbazepine Acetate II-82
Sun Pharma, Lupin and Dr Reddy's Introduce Generic
Schizophrenia Drug II-82
Mylan Launches Levetiracetam in Sodium Chloride Injection II-82
Dr. Reddy’s Laboratories Introduces Generic Antipsychotic Drug II-83
Eisai to Unveil Fycompa Antiepileptic Agent II-83
H. Lundbeck Introduces Sycrest II-83
GW Pharmaceuticals to Develop Cannabis-Based Epileptic
Treatment II-83
Sun Pharmaceutical Unveils Zyprexa Zydis II-84
Eisai to Unveil Zonegran Drug Treatment in Russia II-84
Teva Pharmaceutical Industries Introduces Quetiapine and
Quetiapine XL II-84
Eisai and Nobelpharma to Introduce Fostoin Anticonvulsant
Agent II-84
Janssen Pharmaceuticals Receives Approval for Updated Product
Labeling II-84
H Lundbeck Introduces Onfi Anti-Epileptic Drug in US II-85
Amneal Pharmaceuticals Unveils Felbamate Generic Anti-
Epileptic Drug II-85
Teva UK Unveils Generic Olanzapine for Schizophrenia II-85
Mylan Pharmaceuticals Unveils Divalproex Sodium Capsules USP II-86
Actavis Introduces Generic Olanzapine Tablets II-86
GlaxoSmithKline Introduces Trobalt® Anti-Epileptic Drug II-86
Alkermes Launches Phase III Clinical Trial for Drug Candidate
ALKS 9070 II-86
BIAL and Eisai Unveil Zebinix® Drug in Spain II-86
Amneal Launches AA-Rated Generic Oral Drugs II-86
Orexo Introduces Analgesic Drug Abstral II-87
MSN Laboratories Unveils Tapal for Pain Management II-87
CNS Pain Management Company Introduces Palexia® SR II-87
Glenmark Genetics Introduces New Formulations for Pain
Management II-87
Vanda Pharmaceuticals Introduces Fanapt for Schizophrenia II-88
Roche to Develop RG-1678 Schizophrenia Drug II-88
H. Lundbeck and King's College London Launch Academic-Industry
Collaboration Project II-88
Alkermes Develops LinkeRxâ„¢ technology Platform for CNS
Therapies II-89
Novartis Introduces Fanapt Schizophrenia Drug II-89
Axxess Pharma Signs Agreement to Market Fortex II-89
Nutra Pharma Unveils Cobroxin in CVS II-89

8. RECENT INDUSTRY ACTIVITY II-90
UCB and Otsuka Pharmaceuticals to Develop Anti-Epileptic Drugs II-90
Sunovion Files for Expanded Use of Latuda® II-90
Eisai Receives Manufacturing License in the UK II-90
Dainippon Sumitomo and Takeda Receive Acceptance from the EMA II-90
Lupin Receives FDA Approval to Market Anti-Epileptic Drugs II-91
Dainippon Sumitomo Inks an Agreement with Takeda II-91
Sanofi and Alfresa Pharma Ink Agreement to Develop Vigabatrin II-91
Sunovion Files two sNDAs for Latuda® II-91
Prasco Laboratories Inks Agreement with Shire II-92
Otsuka Files for Additional Indication for Abilify® II-92
Aspen Global to Take Over Drug Portfolio of GlaxoSmithKline II-92
Par Pharmaceutical and Handa Pharmaceuticals Ink Licensing
Agreement II-92
Upsher-Smith Laboratories Takes Over Proximagen Group II-92
Mylan Pharmaceuticals Receives FDA Approval for Lithium
Carbonate Extended-release Tablets USP II-93
Supernus Obtains Approval for Oxtellar XR Anti-Epilepsy Drug II-93
FDA Denies Antipsychotic Drug from Otsuka and Lundbeck II-93
Eisai Receives Approval for Fycompa Drug II-93
Forest Laboratories Submits NDA for Cariprazine II-94
Lupin Pharmaceuticals Obtains Approval for Levetiracetam
Generic Drug II-94
Johnson and Johnson Pays Fine for Illegal Marketing II-94
UCB Discloses Epilepsy Drug Trial Results II-94
GSK Agrees to Pay Criminal Fine for Illegal Promotion II-94
GlaxoSmithKline Obtains Marketing Approval for Trobaltâ„¢ II-94
Novartis Discontinues Development of Fanapt II-95
Qualitest Pharmaceuticals Obtains FDA Approval for
Levetiracetam Tablets II-95
Eisai Europe Obtains Approval for Zonegran® Anti-Epileptic
Agent II-95
Eisai Obtains Approval for Zonegran® II-95
Glenmark Generics Obtains FDA Approval for Lamotrigine II-96
Mylan Obtains FDA Approval for Levetiracetam Extended-Release
Tablets II-96
Forest Laboratories Enters into Broad Strategic Alliance with
moksha8 II-96
moksha8 Extends License Agreement with Watson Pharmaceuticals II-96
Paladin Labs and QRxPharma Sign Licensing Agreement II-97
Mallinckrodt Acquires CNS Therapeutics II-97
Neurodyn Takes Over NeuroQuest II-97
Zogenix Inks Exclusive Co-Promotion Agreement with
Mallinckrodt II-98
Omron Healthcare Unveils Omron electroTHERAPY Pain Relief Unit II-98
Watson Pharmaceuticals Rolls Out REPREXAINTM CIII II-99
INSYS Therapeutics Launches SUBSYSâ„¢ Dosage Form for BTCP
Treatment II-99
Actavis Signs Agreement with QRxPharma to Market MOXDUO® IR II-99
Mallinckrodt Receives FDA Approval for EXALGO® Tablet II-99
Biostar Pharmaceuticals Obtains Army New Drug Certificate for
Zushima Analgesic Spray II-100
Pfizer Receives FDA Approval for Lyrica® Capsules II-100
Teva Acquires Cephalon II-100
Eisai Files for Expanded Use of Zonegran II-100
Johnson and Johnson Recalls Schizophrenia Drug II-101
Intellipharmaceutics Files for NDA Approval for Lamictal XR
Generic Version II-101
BioLineRx Receives New Patent Protection for Schizophrenia
Drug II-101
Aurobindo Pharmaceuticals Obtains FDA Approval for Gabapentin
Tablets II-101
Zogenix Acquires Rights to Utilize Durect’s Technology for
Relday II-101
Unichem Obtains FDA Approval for Lamotrigine Tablets II-102
BioLineRx Signs Agreement with Cypress Bioscience II-102
Eisai Obtains Approval from Health Canada for Banzel II-102
Alkermes Acquires Elan Drug Technologies II-102
Eisai Obtains FDA Approval for Oral Suspension of Banzel II-103
Pfizer Acquires Icagen II-103
Health Canada Grants Approval for Abilify® to Treat
Schizophrenia in Adolescents II-103
GlaxoSmithKline Receives Approval for Rotavirus Vaccine and
Lamictal Tablets II-103
Janssen Obtains Approval for Xeplion from European Commission II-104
Janssen-Cilag Receives FDA Approval for INVEGA® II-104
Janssen-Cilag International Secures EC Approval for INVEGA II-104
Actavis Enters into Letter of Intent with QRxPharma II-104
DSM Pharmaceutical and QRxPharma Ink Manufacturing and Supply
Agreement II-105
UCB Takes Over Key Pharmaceutical Assets of Lectus
Therapeutics II-105
Teva Pharmaceutical Industries Acquires Cephalon II-106
Biotie Therapies Takes Over Newron Pharmaceuticals II-106
RaQualia Pharma Enters into Collaboration with Eli Lilly II-106
Elder Pharmaceuticals to Launch New Therapeutic Products II-107
Lupin Pharmaceuticals Obtains FDA Approval for Tramadol ER
Tablets II-107
Envoy Therapeutics and Takeda Pharmaceutical Form Research
Alliance II-107
Ranbaxy Recalls Anti-Epileptic Drug from UK II-107
H. Lundbeck Inks Global Commercialization Agreement with Merck II-107
Medco Research Institute to Form Alliance with SureGene II-108
Forest Labs and Gruenenthal Sign License Agreement II-108
Endo Pharmaceuticals Holdings Acquires Qualitest
Pharmaceuticals II-108
IntelGenx Inks an Agreement with PediPharm II-109
Insys Therapeutics Merges with NeoPharm II-109
HepaLife Technologies Collaborates with Jeiven Pharmaceutical II-109
Pfizer to Take Over King Pharmaceuticals II-110
The Apothecary Shops Takes Over Greater Sacramento Specialty
Pharmacy II-110
NsGene and Biogen Idec Ink New Commercialization and License
Agreement II-110
Xanodyne Pharmaceuticals Inks Co-Promotion Agreement with
Ferring Pharmaceuticals II-111
QRxPharma Enters into Strategic Alliance with China Aoxing
Pharmaceutical II-111
Pfizer Japan Obtains New Indication Approval for Lyrica®
Capsules II-111
Eli Lilly and Company Receives FDA Approval for Cymbalta II-112

9. FOCUS ON SELECT GLOBAL PLAYERS II-113
AbbVie Inc (USA) II-113
Alkermes Plc (Ireland) II-113
Amneal Pharmaceuticals, LLC (USA) II-114
Aspen Pharmacare Holdings Limited (South Africa) II-115
AstraZeneca Plc (UK) II-115
BEACON Pharmaceutical Limited (UK) II-116
BIAL Group (Portugal) II-116
Boehringer Ingelheim GmbH (Germany) II-116
Bristol-Myers Squibb (USA) II-117
Dainippon Sumitomo Pharma Co., Ltd. (Japan) II-118
Eisai Co., Ltd. (Japan) II-119
Elan Corporation Plc (Ireland) II-120
Eli Lilly and Co. (USA) II-120
F. Hoffmann-La Roche Ltd. (Switzerland) II-121
Fabre-Kramer Pharmaceuticals, Inc. (USA) II-121
Forest Laboratories, Inc. (USA) II-122
GlaxoSmithKline (UK) II-122
H. Lundbeck A/S (Denmark) II-123
Johnson and Johnson (USA) II-124
Janssen Pharmaceuticals, Inc. (USA) II-125
Merck and Co., Inc. (USA) II-125
Neurocrine Biosciences, Inc. (USA) II-125
Novartis AG (Switzerland) II-126
Otsuka Pharmaceutical Co., Ltd. (Japan) II-127
Pfizer, Inc. (USA) II-127
Sanofi S.A (France) II-128
Shire Plc (UK) II-130
Sunovion Pharmaceuticals, Inc. (USA) II-130
Takeda Pharmaceutical Co., Ltd. (Japan) II-130
Teva Pharmaceutical Industries Ltd. (Israel) II-131
UCB Group (Belgium) II-131

10. GLOBAL MARKET PERSPECTIVE II-133
Table 5: World Recent Past, Current and Future Analysis for CNS
Therapeutics by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-133

Table 6: World Historic Review for CNS Therapeutics by
Geographic Region - US, Canada, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) II-134

Table 7: World 15-Year Perspective for CNS Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Europe, Asia-Pacific, Latin America and Rest of
World Markets for the Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) II-135

Table 8: World Recent Past, Current and Future Analysis for
Anti-Alzheimer’s by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-136

Table 9: World Historic Review for Anti-Alzheimer’s by
Geographic Region - US, Canada, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) II-137

Table 10: World 15-Year Perspective for Anti-Alzheimer’s by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Europe, Asia-Pacific, Latin America and Rest of
World Markets for the Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) II-138

Table 11: World Recent Past, Current and Future Analysis for
Anti-Parkinson’s by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-139

Table 12: World Historic Review for Anti-Parkinson’s by
Geographic Region - US, Canada, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) II-140

Table 13: World 15-Year Perspective for Anti-Parkinson’s by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Europe, Asia-Pacific, Latin America and Rest of
World Markets for the Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) II-141

Table 14: World Recent Past, Current and Future Analysis for
Anti-Epilepsy by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-142

Table 15: World Historic Review for Anti-Epilepsy by
Geographic Region - US, Canada, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) II-143

Table 16: World 15-Year Perspective for Anti-Epilepsy by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Europe, Asia-Pacific, Latin America and Rest of
World Markets for the Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) II-144

Table 17: World Recent Past, Current and Future Analysis for
Pain Management by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-145

Table 18: World Historic Review for Pain Management by
Geographic Region - US, Canada, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) II-146

Table 19: World 15-Year Perspective for Pain Management by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Europe, Asia-Pacific, Latin America and Rest of
World Markets for the Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) II-147

Table 20: World Recent Past, Current and Future Analysis for
Anti-Psychotics by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-148

Table 21: World Historic Review for Anti-Psychotics by
Geographic Region - US, Canada, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) II-149

Table 22: World 15-Year Perspective for Anti-Psychotics by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Europe, Asia-Pacific, Latin America and Rest of
World Markets for the Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) II-150

Table 23: World Recent Past, Current and Future Analysis for
Anti-Depressants by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-151

Table 24: World Historic Review for Anti-Depressants by
Geographic Region - US, Canada, Europe, Asia-Pacific, Latin
America and Rest of World Markets Independently Analyzed by
Annual Sales in US$ Million for the Years 2004 through 2009
(includes corresponding Graph/Chart) II-152

Table 25: World 15-Year Perspective for Anti-Depressants by
Geographic Region - Percentage Breakdown of Value Sales for
US, Canada, Europe, Asia-Pacific, Latin America and Rest of
World Markets for the Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) II-153

Table 26: World Recent Past, Current and Future Analysis for
Others by Geographic Region - US, Canada, Europe,
Asia-Pacific, Latin America and Rest of World Markets
Independently Analyzed by Annual Sales in US$ Million for the
Years 2010 through 2018 (includes corresponding Graph/Chart) II-154

Table 27: World Historic Review for Others by Geographic
Region - US, Canada, Europe, Asia-Pacific, Latin America and
Rest of World Markets Independently Analyzed by Annual Sales
in US$ Million for the Years 2004 through 2009 (includes
corresponding Graph/Chart) II-155

Table 28: World 15-Year Perspective for Others by Geographic
Region - Percentage Breakdown of Value Sales for US, Canada,
Europe, Asia-Pacific, Latin America and Rest of World Markets
for the Years 2004, 2012 and 2018 (includes corresponding
Graph/Chart) II-156


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Market Overview III-1
Focus on Select Markets III-1
Alzheimer’s Market III-1
Anti-Epilepsy Market III-1
Epilepsy - A Major Concern for Healthcare Industry III-1
A Glance at Epilepsy Statistics III-2
Anti-Epilepsy Drugs: Market Overview III-2
Table 29: Number of Dispensed Prescriptions in the US
Anti-Epileptic Drugs Market in Million (2007-2012)
(includes corresponding Graph/Chart) III-3
Epilepsy in Children III-3
Growing Competition from Generics III-4
Pain Management Market III-4
Neuropathic Pain Market III-5
Anti-Psychotic Drugs Market III-5
Mental Illnesses - An Epidemiology III-5
Facts and Figures III-5
Table 30: Lifetime Prevalence (%) of Bipolar Disorder in
the US Population by Age Group (includes corresponding
Graph/Chart) III-6
Popular Antipsychotic Drugs in the US III-6
Table 31: Sales of Select Anti-Psychotic Drugs in the US
(2011) (In US$ Million) (includes corresponding
Graph/Chart) III-7
Anti-Psychotic Drugs by FDA Approved Age and Indication
in the US III-7
Table 32: US Anti-Psychotic Drugs Market (2012):
Percentage Breakdown of Value Sales by Indication -
Bipolar Disorder, Schizophrenia, Major Depressive
Disorder, and Others (includes corresponding Graph/Chart) III-8

Table 33: US Antipsychotics Market (2012): Percentage
Share Breakdown of Prescriptions by Indication - Bipolar
Disorder, Schizophrenia, Major Depressive Disorder,
Anxiety, and Others (includes corresponding Graph/Chart) III-8

Table 34: Leading Brands in the US Antipsychotics Market
(2011): Percentage Share Breakdown of Number of
Prescriptions by Seroquel, Abilify, Zyprexa, Geodon,
Seroquel XR and Others (includes corresponding
Graph/Chart) III-8

Table 35: Leading Antipsychotic Brands in the US
Schizophrenia Market (2011): Percentage Share Breakdown
of Number of Prescriptions by Seroquel, Abilify, Zyprexa,
Geodon, Seroquel XR and Others (includes corresponding
Graph/Chart) III-9
Growth Dampeners III-9
Surging Off-label Prescriptions III-9
Advertising for Antipsychotics Acquires a Whole New
Dimension III-10
Table 36: Leading Brands in the US Antipsychotics Market
(2011): Percentage Share Breakdown of Promotional
Spending by Abilify, Seroquel, Saphris, Geodon, Latuda,
Invega, Zyprexa, and Others (includes corresponding
Graph/Chart) III-10
Illegal Marketing - A Cause of Concern for Governments III-10
Generics Occupy Front Seat III-11
Initiatives by Regulatory Bodies Favor Generics III-11
Initiatives to Cut Spending on Antipsychotics III-11
Antipsychotics Use in Nursing Homes Raises Concern III-12
Rising Antipsychotic Use among Children - A Cause of
Concern III-13
Table 37: US Antipsychotics Market (2010): Percentage
Share Breakdown of Number of Prescriptions (to Children)
by Practitioner - Psychiatrist, Pediatrics, Nurse
Practitioners, General Physician, and Others (includes
corresponding Graph/Chart) III-14
Product Launches III-14
Strategic Corporate Developments III-18
Key Players III-29
B.Market Analytics III-37
Table 38: US Recent Past, Current and Future Analysis for CNS
Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-37

Table 39: US Historic Review for CNS Therapeutics by Product
Group - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy,
Pain Management, Anti-Psychotics, Anti-Depressants and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-38

Table 40: US 15-Year Perspective for CNS Therapeutics by
Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for 2004, 2012 and 2018 (includes corresponding
Graph/Chart) III-39

2. CANADA III-40
A.Market Analysis III-40
Current and Future Analysis III-40
CNS Diseases: Facts and Figures III-40
Product Launches III-40
Strategic Corporate Developments III-41
B.Market Analytics III-43
Table 41: Canadian Recent Past, Current and Future Analysis
for CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-43

Table 42: Canadian Historic Review for CNS Therapeutics by
Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-44

Table 43: Canadian 15-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for 2004, 2012 and 2018 (includes corresponding
Graph/Chart) III-45

3. EUROPE III-46
A.Market Analysis III-46
Current and Future Analysis III-46
Pain Management Market III-46
Branded Drugs Feel the Heat of Generic Erosion III-46
Uncertain Future of New Drug Development III-46
Anti-Psychotics Market III-47
An Overview III-47
Demand for Antipsychotics for Bipolar Disorder Upbeat III-48
Table 44: European Atypical Antipsychotics Market (Bipolar
Disorder) (2011): Percentage Share Breakdown of Value
Sales by Seroquel, Abilify, Zyprexa, Geodon, and Others
(includes corresponding Graph/Chart) III-48
Generics to Witness Growth in Bipolar Disorder Therapeutics
Market III-48
Manufacturers Focus on New Drug Formulations III-49
Clinical Pipeline III-49
Product Launches III-49
Strategic Corporate Developments III-50
B.Market Analytics III-53
Table 45: European Recent Past, Current and Future Analysis
for CNS Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain and Rest of Europe Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2010
through 2018 (includes corresponding Graph/Chart) III-53

Table 46: European Historic Review for CNS Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain, and
Rest of Europe Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) III-54

Table 47: European Recent Past, Current and Future Analysis
for CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-55

Table 48: European Historic Review for CNS Therapeutics by
Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-56

Table 49: European 15-Year Perspective for CNS Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales
for France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for Years 2004, 2012 and 2018 (includes
corresponding Graph/Chart) III-57

Table 50: European 15-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for 2004, 2012 and 2018 (includes corresponding
Graph/Chart) III-58

3a. FRANCE III-59
A.Market Analysis III-59
Current and Future Analysis III-59
Product Launch III-59
Sanofi S.A - A Key Player III-59
B.Market Analytics III-61
Table 51: French Recent Past, Current and Future Analysis for
CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-61

Table 52: French Historic Review for CNS Therapeutics by
Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-62

Table 53: French 15-Year Perspective for CNS Therapeutics by
Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for 2004, 2012 and 2018 (includes corresponding
Graph/Chart) III-63

3b. GERMANY III-64
A.Market Analysis III-64
Current and Future Analysis III-64
Boehringer Ingelheim GmbH - A Key Player III-64
B.Market Analytics III-65
Table 54: German Recent Past, Current and Future Analysis for
CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-65

Table 55: German Historic Review for CNS Therapeutics by
Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-66

Table 56: German 15-Year Perspective for CNS Therapeutics by
Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for 2004, 2012 and 2018 (includes corresponding
Graph/Chart) III-67

3c. ITALY III-68
A.Market Analysis III-68
Current and Future Analysis III-68
Market Snapshots III-68
Strategic Corporate Development III-68
B.Market Analytics III-69
Table 57: Italian Recent Past, Current and Future Analysis for
CNS Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-69

Table 58: Italian Historic Review for CNS Therapeutics by
Product Group - Anti-Alzheimer's, Anti-Parkinson's,
Anti-Epilepsy, Pain Management, Anti-Psychotics,
Anti-Depressants and Other Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-70

Table 59: Italian 15-Year Perspective for CNS Therapeutics
by Product Group - Percentage Breakdown of Dollar Sales for
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain
Management, Anti-Psychotics, Anti-Depressants and Other
Markets for 2004, 2012 and 2018 (includes corresponding
Graph/Chart) III-71

3d. THE UNITED KINGDOM III-72
A.Market Analysis III-72
Current and Future Analysis III-72
NICE Recommendations on CNS Therapeutics III-72
Product Launches III-72
Strategic Corporate Developments III-75
Key Players III-76
B.Market Analytics III-80
Table 60: UK Recent Past, Current and Future Analysis for CNS
Therapeutics by Product Group - Anti-Alzheimer's,
Anti-Parkinson's, Anti-Epilepsy, Pain Management,
Anti-Psychotics, Anti-Depressants and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-80

Table 61: UK Historic Review for CNS Therapeutics by Product
Group - Anti-Alzheimer's, Anti-Parkinson's, Anti-E

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

  • $ 4 795
  • Industry report
  • September 2014
  • by Transparency Market Research

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream ...

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech

  • $ 3 295
  • Industry report
  • September 2014
  • by Currentpartnering

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.